Clinical Study of GT719 Injection for Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

by | Apr 29, 2025 | Clinical Trials | 0 comments

​ Conditions: Hematological Malignancy (Leukemia- Lymphoma)

Interventions: Biological: GT719 Injection

Sponsors: Grit Biotechnology

Recruiting Conditions: Hematological Malignancy (Leukemia- Lymphoma)
Interventions: Biological: GT719 Injection
Sponsors: Grit Biotechnology
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *